Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Farhad Sahebkar

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pediatric Neurology|February 20, 2013
Rhomb- and bickerstaff encephalitis: two clinical phenotypes?Rebecca C Gologorsky, Jerome A Barakos, Farhad Sahebkar
Clinical Pharmacokinetics|December 6, 2019
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal ImpairmentBola Tayo, Lesley Taylor, Farhad Sahebkar, et al.
Epilepsia|April 13, 2023
Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trialsStéphane Auvin, Charlotte Nortvedt, Douglas S Fuller, et al.
Cannabis and Cannabinoid Research|May 17, 2021
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal SeizuresMartin J Brodie, Piotr Czapinski, Ladislav Pazdera, et al.
Epilepsia|December 27, 2021
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trialElizabeth A Thiele, E Martina Bebin, Francis Filloux, et al.
Epilepsia Open|August 1, 2024
Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access programArie Weinstock, E Martina Bebin, Daniel Checketts, et al.
Epilepsia|February 17, 2022
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6Joyce Y Wu, Hannah R Cock, Orrin Devinsky, et al.
Epilepsia|December 20, 2022
Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access programJerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, et al.
JAMA Neurology|December 21, 2020
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical TrialElizabeth A Thiele, E Martina Bebin, Hari Bhathal, et al.
Epilepsia|May 27, 2023
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access ProgramRobert J Flamini, Anne M Comi, E Martina Bebin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pediatric Neurology|February 20, 2013
Rhomb- and bickerstaff encephalitis: two clinical phenotypes?Rebecca C Gologorsky, Jerome A Barakos, Farhad Sahebkar
Clinical Pharmacokinetics|December 6, 2019
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal ImpairmentBola Tayo, Lesley Taylor, Farhad Sahebkar, et al.
Epilepsia|April 13, 2023
Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trialsStéphane Auvin, Charlotte Nortvedt, Douglas S Fuller, et al.
Cannabis and Cannabinoid Research|May 17, 2021
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal SeizuresMartin J Brodie, Piotr Czapinski, Ladislav Pazdera, et al.
Epilepsia|December 27, 2021
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trialElizabeth A Thiele, E Martina Bebin, Francis Filloux, et al.
Epilepsia Open|August 1, 2024
Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access programArie Weinstock, E Martina Bebin, Daniel Checketts, et al.
Epilepsia|February 17, 2022
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6Joyce Y Wu, Hannah R Cock, Orrin Devinsky, et al.
Epilepsia|December 20, 2022
Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access programJerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, et al.
JAMA Neurology|December 21, 2020
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical TrialElizabeth A Thiele, E Martina Bebin, Hari Bhathal, et al.
Epilepsia|May 27, 2023
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access ProgramRobert J Flamini, Anne M Comi, E Martina Bebin, et al.
Pageof 1